Marimed (MRMD) Receivables (2011 - 2026)

Marimed (MRMD) has reported Receivables for 15 consecutive years, with $9.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 21.72% year-over-year to $9.4 million in Q2 2026; TTM through Jun 2026 was $9.4 million, a 21.72% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 2.01% from the prior year.
• Receivables was $9.4 million for Q2 2026 at Marimed, down from $9.4 million in the prior quarter.
• Over five years, Receivables peaked at $9.4 million in Q1 2026 and troughed at $4.4 million in Q1 2023.
• A 5-year average of $7.6 million and a median of $7.9 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 447.56% in 2022 and tumbled 48.2% in 2023, its largest moves.
• Over 5 years, Receivables stood at $8.7 million in 2022, then dropped by 9.1% to $7.9 million in 2023, then rose by 13.02% to $9.0 million in 2024, then grew by 1.51% to $9.1 million in 2025, then advanced by 2.68% to $9.4 million in 2026.
• The last three Receivables figures came in at $9.4 million (Q2 2026), $9.4 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.